A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for PTSD (MAPP2)

A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder of Moderate or Greater Severity  

This multi-site, double-blind, placebo-controlled, randomized Phase 3 study assessed the efficacy and safety of MDMA-assisted therapy versus therapy with placebo control in participants diagnosed with at least moderate PTSD. The study was conducted in N ≈ 100 participants. Participants were randomized into one of two groups (MDMA or placebo) in a 1:1 ratio. A flexible dose of MDMA or placebo, followed by a supplemental half-dose unless contraindicated, was administered during the Treatment Period with manualized therapy in three monthly Experimental Sessions. This ~12-week Treatment Period was preceded by three Preparatory Sessions with the participant and therapists. Initial doses in each Experimental Session were 80 mg or 120 mg of MDMA, followed 1.5 to 2 hours later by a supplemental half-dose (40 or 60 mg, respectively). Total amounts of MDMA administered per Experimental Session ranged from 80 mg to 180 mg. Each Experimental Session was followed by three Integrative Sessions of non-drug therapy to help the participants process and understand their experiences during the Experimental Sessions.